GIM
UTHR icon

Glenmede Investment Management’s United Therapeutics UTHR Stock Holding History

Glenmede Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.58M Sell
13,318
-5,949
-31% -$2M 0.03% 428
2025
Q2 		$5.54M Buy
+19,267
New +$5.76M 0.03% 427

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Glenmede Investment Management's UTHR Position: Q3 2025 in Review

Glenmede Investment Management reduced its United Therapeutics (UTHR) stake by 31% in Q3 2025, selling an estimated $2M and leaving 13,318 shares worth $5.58M. The position accounts for 0.03% of the portfolio, ranked #428.

Glenmede Investment Management first reported a position in UTHR in Q2 2025 and has held it in 2 quarters since. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Glenmede Investment Management held 13,318 shares of United Therapeutics worth $5.58M as of Q3 2025.
  • Glenmede Investment Management sold 5,949 United Therapeutics shares in Q3 2025, an estimated $2M.
  • United Therapeutics made up 0.03% of Glenmede Investment Management's portfolio in Q3 2025, its #428 holding.
  • Glenmede Investment Management first reported a position in United Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.